David S. Garvey

2.7k total citations
54 papers, 2.2k citations indexed

About

David S. Garvey is a scholar working on Organic Chemistry, Pharmacology and Molecular Biology. According to data from OpenAlex, David S. Garvey has authored 54 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Organic Chemistry, 25 papers in Pharmacology and 21 papers in Molecular Biology. Recurrent topics in David S. Garvey's work include Inflammatory mediators and NSAID effects (13 papers), Nitric Oxide and Endothelin Effects (10 papers) and Eicosanoids and Hypertension Pharmacology (9 papers). David S. Garvey is often cited by papers focused on Inflammatory mediators and NSAID effects (13 papers), Nitric Oxide and Endothelin Effects (10 papers) and Eicosanoids and Hypertension Pharmacology (9 papers). David S. Garvey collaborates with scholars based in United States, United Kingdom and Spain. David S. Garvey's co-authors include Satoru Masamune, David R. Janero, L. Gordon Letts, Subhash P. Khanapure, Shaikh A. Ali, David L. Snitman, Mark W. Holladay, Masahiro Hirama, James T. Wasicak and James P. Sullivan and has published in prestigious journals such as Journal of the American Chemical Society, Gastroenterology and Journal of Medicinal Chemistry.

In The Last Decade

David S. Garvey

54 papers receiving 2.1k citations

Peers

David S. Garvey
Gerd Dannhardt Germany
Theodore S. Widlanski United States
Michael S. Malamas United States
Jean‐Pierre Hénichart France
Yves Leblanc Canada
Daniela Barlocco Italy
John J. Talley United States
Maurizio Anzini Italy
Lewis D. Pennington United States
Yves Girard Canada
Gerd Dannhardt Germany
David S. Garvey
Citations per year, relative to David S. Garvey David S. Garvey (= 1×) peers Gerd Dannhardt

Countries citing papers authored by David S. Garvey

Since Specialization
Citations

This map shows the geographic impact of David S. Garvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David S. Garvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David S. Garvey more than expected).

Fields of papers citing papers by David S. Garvey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David S. Garvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David S. Garvey. The network helps show where David S. Garvey may publish in the future.

Co-authorship network of co-authors of David S. Garvey

This figure shows the co-authorship network connecting the top 25 collaborators of David S. Garvey. A scholar is included among the top collaborators of David S. Garvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David S. Garvey. David S. Garvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khanapure, Subhash P., David S. Garvey, David R. Janero, & L. Gordon Letts. (2007). Eicosanoids in Inflammation: Biosynthesis, Pharmacology, and Therapeutic Frontiers. Current Topics in Medicinal Chemistry. 7(3). 311–340. 254 indexed citations
2.
Dhawan, Vijay, James L. Ellis, David S. Garvey, et al.. (2005). Synthesis and anti-inflammatory activity of a series of N-substituted naproxen glycolamides: Nitric oxide-donor naproxen prodrugs. Bioorganic & Medicinal Chemistry. 14(8). 2589–2599. 22 indexed citations
3.
Ellis, James L., Edward Cochran, Richard A. Earl, et al.. (2005). NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 12(5-6). 521–534. 10 indexed citations
4.
Garvey, David S., David R. Janero, L. Gordon Letts, et al.. (2005). Design of a Heteroaryl Modified, 1,5-Disubstituted Pyrazole Cyclooxygenase-2 (COX-2) Selective Inhibitor. Letters in Drug Design & Discovery. 2(1). 40–43. 17 indexed citations
5.
Young, Delano V., Edward Cochran, Vijay Dhawan, et al.. (2005). A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochemical Pharmacology. 70(9). 1343–1351. 9 indexed citations
6.
Garvey, David S., David R. Janero, L. Gordon Letts, et al.. (2004). Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles. Bioorganic & Medicinal Chemistry. 12(6). 1357–1366. 60 indexed citations
7.
Earl, Richard A., David S. Garvey, David R. Janero, et al.. (2004). 3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(24). 6049–6052. 43 indexed citations
8.
Garvey, David S., David R. Janero, L. Gordon Letts, et al.. (2004). Combination of Paclitaxel and Nitric Oxide as a Novel Treatment for the Reduction of Restenosis. Journal of Medicinal Chemistry. 47(9). 2276–2282. 22 indexed citations
9.
10.
Lin, Nan‐Horng, David Gunn, Suzanne A. Lebold, et al.. (1999). Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework. Bioorganic & Medicinal Chemistry Letters. 9(18). 2747–2752. 12 indexed citations
11.
Tejada, I Sáenz de, David S. Garvey, L. Gordon Letts, et al.. (1999). Design and evaluation of nitrosylated alpha-adrenergic receptor antagonists as potential agents for the treatment of impotence.. PubMed. 290(1). 121–8. 28 indexed citations
12.
Wang, Shen, David S. Garvey, Jerry D. Cohen, Herman H. Stein, & Saul H. Rosenberg. (1998). Cyclopentanedi- and tricarboxylic acids as squalene synthase inhibitors: Syntheses and evaluation. Bioorganic & Medicinal Chemistry Letters. 8(8). 891–896. 5 indexed citations
13.
Ewing, James F., et al.. (1997). Reactivity of Nitrogen Monoxide Species with NADH: Implications for Nitric Oxide-Dependent Posttranslational Protein Modification. Archives of Biochemistry and Biophysics. 343(1). 131–139. 14 indexed citations
14.
Delyani, John A., Tareck O. Nossuli, Rosario Scalia, et al.. (1996). S-nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium.. Journal of Pharmacology and Experimental Therapeutics. 279(3). 1174–1180. 21 indexed citations
15.
Donnelly‐Roberts, Diana L., David J. Anderson, Murali Gopalakrishnan, et al.. (1996). A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand. Neuropharmacology. 35(6). 725–734. 121 indexed citations
16.
Garvey, David S., James T. Wasicak, Richard L. Elliott, et al.. (1994). Ligands for Brain Cholinergic Channel Receptors: Synthesis and in Vitro Characterization of Novel Isoxazoles and Isothiazoles as Bioisosteric Replacements for the Pyridine Ring in Nicotine. Journal of Medicinal Chemistry. 37(26). 4455–4463. 51 indexed citations
17.
Garvey, David S., James T. Wasicak, John Y. L. Chung, et al.. (1992). Synthesis and in vitro characterization of novel amino terminally modified oxotremorine derivatives for brain muscarinic receptors. Journal of Medicinal Chemistry. 35(9). 1550–1557. 12 indexed citations
18.
Carrera, George M. & David S. Garvey. (1992). Synthesis of novel substituted spirohydantoins. Journal of Heterocyclic Chemistry. 29(4). 847–850. 11 indexed citations
19.
20.
Masamune, Satoru, Shaikh A. Ali, David L. Snitman, & David S. Garvey. (1980). Highly Stereoselective Aldol Condensation Using an Enantioselective Chiral Enolate. Angewandte Chemie International Edition in English. 19(7). 557–558. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerd Dannhardt Breakdown of academic impact, for papers by Theodore S. Widlanski Breakdown of academic impact, for papers by Michael S. Malamas Breakdown of academic impact, for papers by Jean‐Pierre Hénichart Breakdown of academic impact, for papers by Yves Leblanc Breakdown of academic impact, for papers by Daniela Barlocco Breakdown of academic impact, for papers by John J. Talley Breakdown of academic impact, for papers by Maurizio Anzini Breakdown of academic impact, for papers by Lewis D. Pennington Breakdown of academic impact, for papers by Yves Girard
Rankless by CCL
2026